SCHEMBL2803029

SCHEMBL2803029

NS(=O)(=O)c1ccccc1S(=O)(=O)NC(=O)c1ccc(Br)c(OCC(F)(F)C(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.46
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
PAX8 Q06710 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SCN9A Q15858 2/20 0.35
ALKBH2 Q6NS38 1/20 0.34
ALKBH3 Q96Q83 1/20 0.34
FTO Q9C0B1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2805238 0.90 PTGES (0.48) PTGESMAPTKDM4EMEN1HTT
SCHEMBL2802125 0.86 PTGES (0.51) PTGESMAPTMEN1KMT2ALMNA
SCHEMBL978913 0.84 PTGES (0.47) PTGESALKBH2ALKBH3FTO
SCHEMBL2802214 0.84 PTGES (0.47) PTGESMAPTMEN1KMT2ALMNA
SCHEMBL2802236 0.84 PTGES (0.47) PTGESALKBH2ALKBH3FTO
SCHEMBL2802132 0.84 PTGES (0.53) PTGESMAPTKDM4EMEN1HTT
SCHEMBL2803088 0.83 PTGES (0.45) PTGESMAPTSCN9AALKBH2ALKBH3
SCHEMBL2802679 0.82 PTGES (0.48) PTGESMAPTMEN1KMT2ALMNA
SCHEMBL2802184 0.82 PTGES (0.51) PTGESMAPTMEN1KMT2ALMNA
SCHEMBL2803047 0.80 PTGES (0.49) PTGESMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 PTGES 9/4885MAPT 1012/4885KDM4E 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.